Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR Morb Mortal Wkly Rep. Sept.4, 2015 V.64 N.3 P.944-947
Miwako Kobayashi, MD1,2; Nancy M Bennett, MD3,4; Ryan Gierke, MPH1; Olivia Almendares, MSPH1; Matthew R Moore, MD1; Cynthia G. Whitney, MD1; Tamara Pilishvili, MPH1
Two pneumococcal vaccines are currently licensed for use in the United States: the 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc.]) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Pneumovax 23, Merck and Co., Inc.]).
The Advisory Committee on Immunization Practices (ACIP) currently recommends that a dose of PCV13 be followed by a dose of PPSV23 in all adults aged ≥65 years who have not previously received pneumococcal vaccine and in persons aged ≥2 years who are at high risk for pneumococcal disease because of underlying medical conditions (Table) (1–4).
The recommended intervals between PCV13 and PPSV23 given in series differ by age and risk group and the order in which the two vaccines are given (1–4).
On June 25, 2015, ACIP changed the recommended interval between PCV13 followed by PPSV23 (PCV13–PPSV23 sequence) from 6–12 months to ≥1 year for immunocompetent adults aged ≥65 years.
Recommended intervals for all other age and risk groups remain unchanged. This report outlines the rationale for this change and summarizes the evidence considered by ACIP to make this recommendation……..